Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Larry Meneely who wrote (1343)	2/16/2000 12:37:00 PM
From: Larry Meneely	Read Replies (1) \| Respond to of 2344

This press release certainly contains some of the strongest language that I have heard from McPherson to-date: "The first stage of the Phase II trial was a study utilizing a dosage of 1000 mg of BLP25, which has been shown to induce a very strong CTL immune response in six out of eight patients to date. <>To the Company's knowledge, this type of T-cell mediated cellular immune response has never been previously achieved in human carcinoma patients, nor was this level observed in the 20 mg or 200 mg patients in Phase I. Patients are being followed to determine if this increased T-cell response is reflected in an increased survival benefit. This type of immune response is strongly associated with tumour rejection in many pre-clinical animal models." Larry Meneely